Twinbeech Capital LP Immunovant, Inc. Transaction History

Twinbeech Capital LP

  • $4.99 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$25.1 - $31.61 $588,795 - $741,507
23,458 Added 316.96%
30,859 $814,000
Q1 2024

May 15, 2024
BUY
$30.27 - $43.79 $224,028 - $324,089
7,401 New
7,401 $239,000
Q2 2023

Aug 14, 2023
BUY
$14.2 - $23.75 $1.55 Million - $2.6 Million
109,448 New
109,448 $2.08 Million

Others Institutions Holding IMVT

# of Institutions
211
Shares Held
66.9M
Call Options Held
2.3M
Put Options Held
631K
View Full List

About Immunovant, Inc.

IMVT Quotes by TradingView
  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Twinbeech Capital LP Portfolio

Follow Twinbeech Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Twinbeech Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email